The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

"Declaration of personal interests : David A. Peura, MD, has served as a consultant for Novartis Consumer Products and AstraZeneca; and as a consultant and speaker for Takeda Pharmaceuticals North America, Inc. Barbara Hunt, MS, Betsy Pilmer, RN, BSN and M. Claudia Perez, MD, are employees of Takeda Global Research & Development Center, Inc, Deerfield, IL, USA. Reema Mody, MBA, PhD, is an employee of Takeda Pharmaceuticals International, Inc, Deerfield, IL, USA. Declaration of funding interests : This analysis, along with the original studies ( http://Clinicaltrials.gov NCT#00251693, NCT00251719, NCT00321984) was sponsored by Takeda Global Research & Development Center, Inc, Deerfield, IL, USA. Writing support was provided by Meryl Gersh, PhD, of AlphaBioCom LLC, King of Prussia, PA, and was funded by Takeda Pharmaceuticals United States of America, Inc."

"Declaration of funding interests: This analysis, along with the original studies (http://Clinicaltrials.gov NCT#00251693, NCT00251719, NCT00321984) was sponsored by Takeda Global Research & Development Center, Inc, Deerfield, IL, USA. Writing support was provided by Meryl Gersh, PhD, of AlphaBioCom LLC, King of Prussia, PA, and was funded by Takeda Pharmaceuticals United States of America, Inc."